Topical bevacizumab for corneal neovascularization after penetrating keratoplasty
| Autor: | S. K. Pandey, Poonam Kishore, Sandeep Saxena, Mohit Khattri, Dipak Kumar |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Graft Rejection
Male Vascular Endothelial Growth Factor A medicine.medical_specialty Visual acuity genetic structures Bevacizumab Administration Topical Visual Acuity Angiogenesis Inhibitors Antibodies Monoclonal Humanized 03 medical and health sciences 0302 clinical medicine Ophthalmology medicine Humans Corneal Neovascularization Graft rejection business.industry Antibodies Monoclonal General Medicine Middle Aged medicine.disease eye diseases Left eye Treatment Outcome Corneal neovascularization 030221 ophthalmology & optometry Corneal vascularization sense organs medicine.symptom business 030217 neurology & neurosurgery Keratoplasty Penetrating medicine.drug |
| Zdroj: | European journal of ophthalmology. 19(5) |
| ISSN: | 1120-6721 |
| Popis: | PURPOSE To evaluate the efficacy of topical bevacizumab for corneal neovascularization in graft rejection. METHODS A 55-year-old man presented with corneal neovascularization and graft rejection 6 months following penetrating keratoplasty (triple procedure) in the left eye. His best-corrected visual acuity (BCVA) was counting fingers at 1 meter. He was administered topical bevacizumab (4 mg/4 mL) in a dose of one drop twice a day for 15 days. No adjunct therapy was given during bevacizumab administration. RESULTS After 1 month, his BCVA improved to 20/120. Corneal vascularization and stromal haze regressed. After 6 months, his BCVA improved to 20/60 with further regression in corneal vascularization and stromal haze. At 9-month follow-up, he maintained BCVA of 20/60. CONCLUSIONS Short-term topical bevacizumab therapy may potentially offer a safer and more effective alternative in treating graft rejection after penetrating keratoplasty. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|